What is CEL-SCI Corp's earnings per share (EPS)?

CEL-SCI Corp (CVM) reported diluted earnings per share of -$6.27 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

CEL-SCI Corp Financials

CVM

FY2025 annual

Revenue Not reported for FY2025

Net Income -$25.4M +5.6% YoY

EPS (Diluted) -$6.27 YoY not available

Free Cash Flow -$17.2M +9.2% YoY

Source SEC Filings (10-K/10-Q) Data as of Jun 30, 2026 Currency USD FYE September

This page shows CEL-SCI Corp (CVM) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CVM FY2025 2026-05-15

CEL-SCI’s statements show a cash-funded development model where financing inflows, rather than operations, sustain the balance sheet.

Cash nearly tripled from $4.1M in FY2023 to $11.0M in FY2025 even though operating cash flow stayed negative. That stronger liquidity came from $42.9M of combined financing cash inflows across FY2024-FY2025, which means the healthier cash position reflects fresh capital more than any change in self-funding ability.

The burn is mostly operating expense burn, not heavy reinvestment: FY2025 capital spending was just $38K against $17.1M of negative operating cash flow. That makes the model asset-light but funding-dependent, with cash consumed mainly by research and overhead rather than by building physical capacity.

Net loss narrowed from $32.4M in FY2023 to $25.4M in FY2025, and operating cash outflow improved alongside it, so the accounting losses broadly reflect real cash use rather than a large non-cash distortion. But because R&D spend fell from $22.5M to $15.9M over the same span, the improvement looks more like spending restraint than the emergence of a self-sustaining commercial engine.

Financial Health Signals

Financial health score not available

CEL-SCI Corp does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

3/6

CEL-SCI Corp passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing

N/A

CEL-SCI Corp reported a net loss of $25.4M while operations used $17.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

CEL-SCI Corp reported an operating loss of $24.8M against $649K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$22.8M

YoY+6.0%

CEL-SCI Corp's EBITDA was -$22.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 6.0% from the prior year.

Net Income

-$25.4M

YoY+5.6%

CEL-SCI Corp reported -$25.4M in net income in fiscal year 2025. This represents an increase of 5.6% from the prior year.

EPS (Diluted)

-$6.27

CEL-SCI Corp earned -$6.27 per diluted share (EPS) in fiscal year 2025.

Revenue

Not reported for fiscal year 2025.

Cash & Balance Sheet

Free Cash Flow

-$17.2M

YoY+9.2%

CEL-SCI Corp recorded an outflow of $17.2M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 9.2% from the prior year.

Cash & Debt

$11.0M

YoY+131.2%

5Y CAGR-6.7%

10Y CAGR+6.7%

CEL-SCI Corp held $11.0M in cash against $5.7M in long-term debt as of fiscal year 2025.

Shares Outstanding

CEL-SCI Corp had 8M shares outstanding in fiscal year 2025.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Return on Equity

-159.3%

YoY+50.0pp

5Y CAGR-5.9pp

CEL-SCI Corp's ROE was -159.3% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 50.0 percentage points from the prior year.

Gross Margin

Not reported for fiscal year 2025.

Operating Margin

Not reported for fiscal year 2025.

Net Margin

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$15.9M

YoY-12.5%

5Y CAGR-2.3%

10Y CAGR-1.9%

CEL-SCI Corp invested $15.9M in research and development in fiscal year 2025. This represents a decrease of 12.5% from the prior year.

Capital Expenditures

$38K

YoY-59.8%

5Y CAGR-57.2%

10Y CAGR-6.3%

CEL-SCI Corp invested $38K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 59.8% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

CVM Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

CVM annual income statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$264K+65.5%	$160K-37.3%	$255K-73.4%	$956K
R&D Expenses	N/A	$15.9M-12.5%	$18.2M-19.2%	$22.5M-11.4%	$25.4M+9.7%	$23.1M+29.5%	$17.8M+40.9%	$12.7M+16.0%	$10.9M-30.1%	$15.6M-10.5%	$17.4M-9.1%	$19.2M+25.7%	$15.3M+20.4%	$12.7M+22.3%	$10.4M-11.7%	$11.7M
SG&A Expenses	N/A	$8.9M+8.9%	$8.2M-9.0%	$9.0M-15.9%	$10.7M-18.2%	$13.1M+11.8%	$11.7M+46.3%	$8.0M+26.3%	$6.3M+9.2%	$5.8M-10.6%	$6.5M-53.2%	$13.9M+29.9%	$10.7M+52.7%	$7.0M+5.9%	$6.6M-1.0%	$6.7M
Operating Income	N/A	-$24.8M+5.9%	-$26.4M+16.3%	-$31.5M+12.7%	-$36.1M+0.4%	-$36.2M-24.9%	-$29.0M-43.5%	-$20.2M-20.4%	-$16.8M+21.7%	-$21.4M+9.5%	-$23.6M+27.0%	-$32.4M-26.2%	-$25.7M-29.2%	-$19.9M-15.2%	-$17.2M+4.1%	-$18.0M
Interest Expense	N/A	$649K-13.0%	$746K+10.5%	$675K-37.5%	$1.1M+194.1%	-$1.1M-195.8%	$1.2M+166.8%	-$1.8M	N/A	N/A	-$1.9M-1545.9%	$130K-20.6%	$164K-3.9%	$170K-35.0%	$262K-18.8%	$323K
Net Income	N/A	-$25.4M+5.6%	-$26.9M+16.8%	-$32.4M+11.8%	-$36.7M-0.9%	-$36.4M-20.2%	-$30.3M-36.7%	-$22.1M+30.5%	-$31.8M-121.7%	-$14.4M-24.8%	-$11.5M+66.8%	-$34.7M-26.8%	-$27.4M-198.3%	-$9.2M+40.7%	-$15.5M+39.8%	-$25.7M
EPS (Diluted)	—	-$6.27	-$15.31	-$0.73+16.1%	-$0.87+3.3%	-$0.90-9.8%	-$0.82-15.5%	-$0.71	-$1.87	-$1.91	-$2.37+77.5%	-$10.51	-$12.21	-$0.66+15.4%	-$0.78+47.7%	-$1.49

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
R&D Expenses	$3.6M-3.1%	$3.8M+2.4%	$3.7M	N/A	$3.7M-6.8%	$4.0M-9.4%	$4.4M	N/A
SG&A Expenses	$1.9M+22.3%	$1.6M-7.8%	$1.7M	N/A	$1.7M-26.5%	$2.4M-3.4%	$2.5M	N/A
Operating Income	-$5.6M-4.3%	-$5.3M+0.8%	-$5.4M	N/A	-$5.5M+14.2%	-$6.4M+7.2%	-$6.9M	N/A
Interest Expense	$111K-5.1%	$117K+33.0%	$88K	N/A	$172K-3.4%	$178K+4.7%	$170K	N/A
Net Income	-$5.7M-3.7%	-$5.5M+0.1%	-$5.5M	N/A	-$5.7M+13.8%	-$6.6M+7.1%	-$7.1M	N/A
EPS (Diluted)	-$0.47	-$0.67+1.5%	-$0.68	N/A	-$1.36	-$2.33+28.3%	-$3.25	N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.

TTM is the trailing twelve months, Q4 FY2025 through Q3 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.

CVM Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

CVM annual balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$28.2M+4.3%	$27.0M-11.6%	$30.5M-39.6%	$50.5M-33.4%	$75.9M+87.2%	$40.5M+46.7%	$27.6M-6.6%	$29.6M+29.1%	$22.9M-7.9%	$24.9M-12.8%	$28.6M+48.5%	$19.2M+77.4%	$10.8M-32.5%	$16.1M-13.7%	$18.6M
Current Assets	$11.6M+91.5%	$6.1M-12.5%	$6.9M-72.8%	$25.4M-43.8%	$45.3M+155.8%	$17.7M+80.3%	$9.8M-14.2%	$11.4M+170.0%	$4.2M-22.4%	$5.5M-34.6%	$8.3M-28.4%	$11.6M+363.8%	$2.5M-66.2%	$7.4M-17.5%	$9.0M
Cash & Equivalents	$11.0M+131.2%	$4.7M+14.3%	$4.1M-81.7%	$22.7M-37.1%	$36.1M+132.5%	$15.5M+83.7%	$8.4M-18.1%	$10.3M+335.1%	$2.4M-18.8%	$2.9M-49.0%	$5.7M-32.7%	$8.5M+20359.5%	$42K-98.9%	$3.9M-7.5%	$4.3M
Inventory	N/A	$1.0M-54.6%	$2.2M+12.3%	$2.0M-0.2%	$2.0M+144.7%	$820K+4.8%	$782K+21.3%	$645K-4.1%	$673K-33.3%	$1.0M-28.0%	$1.4M-3.5%	$1.5M+42.8%	$1.0M-26.6%	$1.4M-11.9%	$1.6M
Accounts Receivable	N/A	N/A	N/A	$0-100.0%	$55K0.0%	$55K-12.5%	$63K-47.1%	$119K-45.7%	$218K-44.6%	$395K+352.4%	$87K+6.6%	$82K+10.2%	$74K-53.2%	$159K-65.3%	$457K
Total Liabilities	$12.2M-13.6%	$14.1M-18.4%	$17.3M-5.7%	$18.4M-5.0%	$19.3M-7.1%	$20.8M-7.5%	$22.5M-24.0%	$29.6M+12.7%	$26.3M+2.7%	$25.6M-23.3%	$33.3M+279.1%	$8.8M+112.3%	$4.1M-54.2%	$9.0M-5.3%	$9.5M
Current Liabilities	$5.1M+11.2%	$4.6M-17.4%	$5.6M+19.8%	$4.7M+18.5%	$3.9M-7.7%	$4.3M+41.3%	$3.0M-67.3%	$9.2M-14.9%	$10.8M+170.3%	$4.0M-40.2%	$6.7M+112.7%	$3.2M-11.1%	$3.5M+85.4%	$1.9M-73.5%	$7.2M
Long-Term Debt	$5.7M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$16.0M+24.0%	$12.9M-2.6%	$13.2M-58.9%	$32.2M-43.1%	$56.5M+186.6%	$19.7M+284.3%	$5.1M+560344.0%	$916+100.0%	-$3.3M-391.3%	-$679K+85.7%	-$4.8M-144.2%	$10.8M+61.0%	$6.7M-4.7%	$7.0M-22.6%	$9.1M
Retained Earnings	-$539.4M-4.9%	-$514.0M-5.5%	-$487.1M-7.1%	-$454.9M-8.8%	-$418.2M-9.5%	-$381.8M-7.9%	-$353.7M-6.7%	-$331.6M-10.6%	-$299.8M-5.0%	-$285.4M-4.2%	-$273.9M-14.5%	-$239.2M-12.9%	-$211.8M-4.4%	-$203.0M-8.3%	-$187.5M

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Total Assets	$21.4M+20.6%	$17.7M-22.7%	$22.9M-18.7%	$28.2M+38.5%	$20.3M-6.7%	$21.8M-15.1%	$25.7M-4.8%	$27.0M
Current Assets	$7.5M+159.3%	$2.9M-58.8%	$7.0M-39.4%	$11.6M+342.2%	$2.6M-13.2%	$3.0M-48.4%	$5.9M-3.3%	$6.1M
Cash & Equivalents	$6.5M+245.2%	$1.9M-69.9%	$6.3M-42.7%	$11.0M+511.0%	$1.8M-6.8%	$1.9M-58.3%	$4.6M-2.6%	$4.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1.0M
Total Liabilities	$10.4M-4.0%	$10.8M-7.9%	$11.8M-3.6%	$12.2M-8.4%	$13.3M-3.6%	$13.8M-4.0%	$14.4M+1.9%	$14.1M
Current Liabilities	$5.1M+5.7%	$4.8M-4.6%	$5.0M-1.8%	$5.1M-8.6%	$5.6M+2.1%	$5.5M+0.4%	$5.5M+18.7%	$4.6M
Long-Term Debt	N/A	N/A	N/A	$5.7M	N/A	N/A	N/A	N/A
Total Equity	$11.0M+59.4%	$6.9M-38.3%	$11.1M-30.2%	$16.0M+127.1%	$7.0M-12.2%	$8.0M-29.3%	$11.3M-12.1%	$12.9M
Retained Earnings	-$556.0M-1.0%	-$550.4M-1.0%	-$544.9M-1.0%	-$539.4M-1.1%	-$533.3M-1.1%	-$527.7M-1.3%	-$521.1M-1.4%	-$514.0M

Not reported in any period shown, so not listed: Goodwill.

CVM Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

CVM annual cash flow statement

Metric	TTM	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	-$16.7M	-$17.1M+9.0%	-$18.8M+17.7%	-$22.8M-25.3%	-$18.2M+2.9%	-$18.8M-23.0%	-$15.3M+6.4%	-$16.3M-21.9%	-$13.4M+2.9%	-$13.8M+40.2%	-$23.1M+3.2%	-$23.8M-3.9%	-$22.9M-69.2%	-$13.5M-11.1%	-$12.2M+46.0%	-$22.6M
Capital Expenditures	$5K	$38K-59.8%	$95K-73.8%	$362K-43.3%	$638K-92.9%	$9.0M+239.6%	$2.7M+1393.4%	-$178K+17415.2%	$1K-90.4%	$11K-66.5%	$31K-57.2%	$73K-29.4%	$104K+1.9%	$102K+86.7%	$55K-74.8%	$217K
Free Cash Flow	-$16.8M	-$17.2M+9.2%	-$18.9M+18.5%	-$23.2M-22.9%	-$18.9M+32.1%	-$27.8M-55.1%	-$17.9M-8.7%	-$16.5M-23.2%	-$13.4M+3.0%	-$13.8M+40.3%	-$23.1M+3.3%	-$23.9M-3.8%	-$23.0M-68.7%	-$13.7M-11.5%	-$12.2M+46.2%	-$22.8M
Investing Cash Flow	-$5K	-$38K+64.7%	-$108K+71.0%	-$372K-106.8%	$5.5M+136.2%	-$15.2M-463.5%	-$2.7M-702.4%	-$336K-477.6%	-$58K-242.0%	-$17K+50.3%	-$34K+63.4%	-$94K+32.6%	-$139K-4.6%	-$133K+0.6%	-$134K+58.0%	-$318K
Financing Cash Flow	$21.5M	$23.4M+19.8%	$19.5M+315.6%	$4.7M+835.3%	-$638K-101.2%	$54.5M+117.8%	$25.0M+69.3%	$14.8M-30.8%	$21.4M+61.3%	$13.3M-34.7%	$20.3M-3.9%	$21.1M-33.0%	$31.5M+222.4%	$9.8M-18.5%	$12.0M+2021.3%	$566K

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Operating Cash Flow	-$4.0M-0.2%	-$4.0M0.0%	-$4.0M+13.9%	-$4.7M-18.6%	-$3.9M+9.8%	-$4.4M-5.5%	-$4.1M+14.0%	-$4.8M
Capital Expenditures	$0	$0	$0-100.0%	$5K	$0	$0-100.0%	$33K+66.8%	$20K
Free Cash Flow	-$4.0M-0.2%	-$4.0M0.0%	-$4.0M+14.0%	-$4.7M-18.7%	-$3.9M+9.8%	-$4.4M-4.7%	-$4.2M+13.7%	-$4.8M
Investing Cash Flow	$0	$0	$0+100.0%	-$5K	$0	$0+100.0%	-$33K-66.8%	-$20K
Financing Cash Flow	$8.7M+2478.3%	-$364K+44.3%	-$654K-104.7%	$13.8M+263.3%	$3.8M+126.7%	$1.7M-58.5%	$4.0M-55.9%	$9.2M

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

CVM Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

CVM annual financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-9721.4%	-12450.1%	-6772.3%	-1881.0%
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-10359.6%	-5746.8%	-6078.8%	-2689.1%
Return on Equity	-159.3%+50.0pp	-209.2%+35.7pp	-244.9%-130.8pp	-114.1%-49.8pp	-64.3%+89.1pp	-153.4%+277.8pp	-431.2%+3475246.2pp	-3475677.4%	N/A	N/A	N/A	-253.7%-116.8pp	-136.9%+83.4pp	-220.2%+63.0pp	-283.2%
Return on Assets	-90.3%+9.5pp	-99.7%+6.3pp	-106.0%-33.4pp	-72.6%-24.7pp	-47.9%+26.7pp	-74.6%+5.5pp	-80.1%+27.5pp	-107.6%-45.0pp	-62.7%-16.4pp	-46.3%+75.2pp	-121.5%+20.7pp	-142.2%-57.6pp	-84.6%+11.7pp	-96.3%+41.7pp	-138.1%
Current Ratio	2.26+0.9x	1.31+0.1x	1.24-4.2x	5.45-6.0x	11.50+7.3x	4.15+0.9x	3.25+2.0x	1.24+0.8x	0.39-1.0x	1.36+0.1x	1.24-2.5x	3.69+3.0x	0.71-3.2x	3.89+2.6x	1.25
Debt-to-Equity	0.36-0.7x	1.10-0.2x	1.31+0.7x	0.57+0.2x	0.34-0.7x	1.05-3.3x	4.38-32294.2x	32298.59	N/A	N/A	N/A	0.81+0.2x	0.62-0.7x	1.29+0.2x	1.05
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	-8723.1%	-8553.9%	-4809.2%	-2381.6%

Metric	Q3'26	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24
Return on Equity	-51.7%+27.8pp	-79.5%-30.4pp	-49.1%	N/A	-80.6%+1.5pp	-82.2%-19.6pp	-62.5%	N/A
Return on Assets	-26.5%+4.3pp	-30.9%-7.0pp	-23.9%	N/A	-27.9%+2.3pp	-30.1%-2.6pp	-27.5%	N/A
Current Ratio	1.48+0.9x	0.60-0.8x	1.39-0.9x	2.26+1.8x	0.47-0.1x	0.55-0.5x	1.07-0.2x	1.31
Debt-to-Equity	0.95-0.6x	1.58+0.5x	1.06+0.7x	0.36-1.5x	1.89+0.2x	1.73+0.5x	1.27+0.2x	1.10

Not reported in any period shown, so not listed: Gross Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Similar Companies

Igm Biosciences, Inc. IGMS

$76.6M

Anebulo Pharmaceuticals Inc ANEB

$14.7M

Adicet Bio Inc ACET

$88.8M

Atara Biotherape ATRA

$96.4M

Immunic Inc IMUX

$224.5M

Where CEL-SCI Corp Ranks

Frequently Asked Questions

Is CEL-SCI Corp profitable?

No, CEL-SCI Corp (CVM) reported a net income of -$25.4M in fiscal year 2025.

What is CEL-SCI Corp's EBITDA?

CEL-SCI Corp (CVM) had EBITDA of -$22.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does CEL-SCI Corp have?

As of fiscal year 2025, CEL-SCI Corp (CVM) had $11.0M in cash and equivalents against $5.7M in long-term debt.

What is CEL-SCI Corp's return on equity (ROE)?

CEL-SCI Corp (CVM) has a return on equity of -159.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is CEL-SCI Corp's free cash flow?

CEL-SCI Corp (CVM) recorded an outflow of $17.2M in free cash flow during fiscal year 2025. This represents a 9.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is CEL-SCI Corp's operating cash flow?

CEL-SCI Corp (CVM) recorded an outflow of $17.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are CEL-SCI Corp's total assets?

CEL-SCI Corp (CVM) had $28.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are CEL-SCI Corp's capital expenditures?

CEL-SCI Corp (CVM) invested $38K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does CEL-SCI Corp spend on research and development?

CEL-SCI Corp (CVM) invested $15.9M in research and development during fiscal year 2025.

How many shares does CEL-SCI Corp have outstanding?

CEL-SCI Corp (CVM) had 8M shares outstanding as of fiscal year 2025.

What is CEL-SCI Corp's current ratio?

CEL-SCI Corp (CVM) had a current ratio of 2.26 as of fiscal year 2025, which is generally considered healthy.

What is CEL-SCI Corp's debt-to-equity ratio?

CEL-SCI Corp (CVM) had a debt-to-equity ratio of 0.36 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is CEL-SCI Corp's return on assets (ROA)?

CEL-SCI Corp (CVM) had a return on assets of -90.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is CEL-SCI Corp's cash runway?

Based on fiscal year 2025 data, CEL-SCI Corp (CVM) had $11.0M in cash against an annual operating cash burn of $17.1M. This gives an estimated cash runway of approximately 8 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is CEL-SCI Corp's Piotroski F-Score?

CEL-SCI Corp (CVM) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are CEL-SCI Corp's earnings high quality?

CEL-SCI Corp (CVM) reported a net loss of $25.4M while operations used $17.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can CEL-SCI Corp cover its interest payments?

CEL-SCI Corp (CVM) reported an operating loss of $24.8M against $649K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.